Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis

作者：Lainer Carr Dahlia; Brahn Ernest^*

来源：Nature Clinical Practice Rheumatology, 2007, 3(8): 434-442.

DOI：10.1038/ncprheum0559

• angiogenesis inhibition
• pannus suppression
• rheumatoid arthritis
• suppression of neovascularization
• vascular endothelial growth factor

Angiogenesis inhibition, long studied in the treatment of malignancies, has begun to emerge as a potential therapeutic approach in managing inflammatory arthritis, particularly rheumatoid arthritis. The growth of new vessels required for the development of the rheumatoid pannus, which then leads to extensive synovial inflammation and joint destruction. Vascular endothelial growth factor is the best studied mediator of angiogenesis, and several therapies have been developed that specifically target this molecule. Several other angiogenesis mediators, such as the angiopoietin-TIE system, hypoxia inducible factor and integrin alpha(V)beta(3), as well as naturally occurring inhibitors of angiogenesis, are also being investigated as potential therapeutic targets. Additionally, there are a number of drugs, including paclitaxel, 2-methoxyestradiol and fumagillin analogs, that might have a role in inhibiting angiogenesis and, thus, in treating proliferative synovitis.

• 出版日期2007-8